Plutux

Healthcare

Trial data, approvals, and what they are worth

Readouts, FDA decisions, drug pricing and payer behaviour, sized in revenue rather than in press-release adjectives.

What Big Funds Own22 fundsWhat Berkshire, Bridgewater and other big funds reported holding last quarter.What Analysts Expect16 stocksRatings and price targets from the big institutions, each with its public source.

2026-08-28

ImmunityBio needs one “week 104” proof point to compete with big-pharma’s mRNA oncology winners insight cover
Industry News
IBRX•7 min read

ImmunityBio needs one “week 104” proof point to compete with big-pharma’s mRNA oncology winners

A fresh milestone update tied to ImmunityBio’s Chairman Patrick Soon-Shiong said the company’s cancer-vaccine trial has been fully accrued and reached its one-year mark, with the primary assessment at week 104 expected around 2027. The market read-through is straightforward: if this non-mRNA platform can translate a process milestone into credible efficacy data on a competitive oncology timeline, ImmunityBio could earn a larger share of investor attention currently dominated by mRNA oncology optimism.

FY2025 revenue: $113.3MFY2025 operating cash flow: -$304.9M
Read article
PhRMA’s Medicare-negotiation bid just failed—IRA drug price cuts shift from legal risk to a permanent revenue-mix problem insight cover
Industry News
8 min read

PhRMA’s Medicare-negotiation bid just failed—IRA drug price cuts shift from legal risk to a permanent revenue-mix problem

On Aug. 27, 2026, the U.S. Court of Appeals for the Fifth Circuit upheld the Medicare Drug Price Negotiation Program after PhRMA’s legal challenge was rebuffed. That outcome turns IRA-negotiated Part D pricing into a durability factor investors must underwrite: revenue now depends on how much of each company’s U.S. demand sits inside the negotiated “maximum fair price” lane (and how aggressively launches and contract structures adapt).

Start date for negotiated prices (first cycle): Jan. 1, 2026Selected-drug share of Part D gross costs (2023): ~20%
Read article

2026-08-27

AstraZeneca and Amgen's Tezspire win in EoE tests whether the ‘late-stage discount’ finally flips on a GI bellwether insight cover
Industry News
AZN · AMGN•8 min read

AstraZeneca and Amgen's Tezspire win in EoE tests whether the ‘late-stage discount’ finally flips on a GI bellwether

AstraZeneca and Amgen say Tezspire (tezepelumab) delivered positive Phase 3 results in eosinophilic oesophagitis (EoE), meeting co-primary endpoints at Week 24 in the CROSSING trial and sustaining improvements through Week 52. The investor question is not just efficacy—it’s whether a confirmed late-stage readout in a Dupixent-adjacent GI indication meaningfully reduces the pipeline execution risk that has recently pressured AstraZeneca’s growth narrative.

Trial & endpoints: CROSSING, Week 24 co-primariesHistologic remission definition: <= 6 eosinophils/HPF
Read article
J&J’s Imaavy approval turns wAIHA into the anti‑FcRn class’s first real pricing proving ground—and raises the bar for argenx’s Vyvgart insight cover
Industry News
ARGX · JNJ•7 min read

J&J’s Imaavy approval turns wAIHA into the anti‑FcRn class’s first real pricing proving ground—and raises the bar for argenx’s Vyvgart

On Aug. 24, 2026, the FDA approved Janssen’s Imaavy (nipocalimab-aahu) as the first treatment specifically cleared for warm autoimmune hemolytic anemia (wAIHA). Because this is the first commercially approved test of the anti‑FcRn mechanism in wAIHA, the launch will quickly become a benchmark that shapes payer and physician expectations for future FcRn expansions—including whether Vyvgart remains the default reference point within the class.

Primary efficacy endpoint (trial-defined durable: Durable Hgb responseEarly effect (hemoglobin change): +1 g/dL at Week 1
Read article
Moderna’s $2B convertible bets oncology—dilution math hinges on capped calls, not the headline bond size insight cover
Industry News
MRNA•8 min read

Moderna’s $2B convertible bets oncology—dilution math hinges on capped calls, not the headline bond size

Moderna MRNA announced a $2.0B private placement of convertible senior notes due 2032 to fund oncology growth flexibility and repayment of debt, while also paying for capped-call hedges to limit dilution. The “bull trap” debate is less about whether the company needs cash and more about whether the equity’s implied conversion path is realistic given the capped premium and Moderna’s persistent cash burn.

Convertible offering size: $2.0BMaturity: 2032
Read article
Novo Nordisk clears China NMPA acceptance for an oral Wegovy bid—shifting the obesity “pill-first” battlefield toward price-controlled, domestic-led competition insight cover
Industry News
NVO•8 min read

Novo Nordisk clears China NMPA acceptance for an oral Wegovy bid—shifting the obesity “pill-first” battlefield toward price-controlled, domestic-led competition

China’s NMPA has accepted Novo Nordisk’s application to sell an oral version of Wegovy, giving Novo a first-mover regulatory position in the world’s second-largest obesity market. The bigger investment story is how China’s price controls and fast-growing domestic oral GLP-1 copycats can compress Novo’s China margin upside, even as the oral category expands the global TAM for semaglutide-class therapies.

Novo Nordisk revenue (TTM): $329,431,000,000Novo Nordisk operating cash flow (TTM): $133,009,000,000
Read article
Veeva’s Q2 FY2027 print answers the “seat cuts vs. surprises” question: R&D/Quality growth stayed intact insight cover
Earnings
VEEV•8 min read

Veeva’s Q2 FY2027 print answers the “seat cuts vs. surprises” question: R&D/Quality growth stayed intact

In Veeva June-ending Q2 FY2027 (ended Jul 31, 2026), total revenue grew 18% year over year and subscription revenue grew 16% year over year, with R&D and Quality Solutions delivering $419.4M in the quarter. The release also points to continued Development Cloud/Quality Cloud adoption and a large biopharma selecting Veeva EDC—suggesting that “budget tightening” shows up more as deal timing and mix, not wholesale seat loss.

Q2 FY2027 total revenue: $928.0MQ2 FY2027 total revenue growth: 18%
Read article

2026-08-26

Boston Scientific's cyberattack hits order/shipping systems—so medtech investors should price a new “working-capital + revenue-timing” risk insight cover
Industry News
BSX•7 min read

Boston Scientific's cyberattack hits order/shipping systems—so medtech investors should price a new “working-capital + revenue-timing” risk

Boston Scientific BSX disclosed a global cyberattack that disrupted operations and is expected to continue limiting access to systems that support “the ability to process and ship customer orders.” The immediate market question isn’t just whether product manufacturing stopped—it’s whether order intake and fulfillment delays push revenue recognition into later quarters and increase working-capital and charge risk at the same time BSX is running a large restructuring program.

Q2 FY2026 revenue: $5.44BQ2 FY2026 net income: $907M
Read article
FDA clears the first continuous dual glucose–ketone wearable—turning CGM into the metabolic control panel the GLP-1 era never had insight cover
Industry News
ABT•8 min read

FDA clears the first continuous dual glucose–ketone wearable—turning CGM into the metabolic control panel the GLP-1 era never had

On Aug 25, 2026, the FDA authorized Abbott’s Libre Duo 10 Day as the first wearable in the U.S. to continuously monitor both ketones and glucose in a single device, primarily to provide earlier warning of rising ketones that can precede diabetic ketoacidosis. The upgrade matters for investors because it expands the measurement layer of metabolic health beyond diabetes, and it forces a new competitive map for CGM-like “sensor + app + alerts + integrations” platforms across the obesity/GLP-1 value chain.

Clinical program size: 600+ participantsBackground monitoring claim: Every minute
Read article
Generate Biomedicines’ lock-up expiry isn’t “just” an overhang—it’s a test of how scarce investors view AI-native protein design insight cover
IPO
8 min read

Generate Biomedicines’ lock-up expiry isn’t “just” an overhang—it’s a test of how scarce investors view AI-native protein design

Generate Biomedicines’ post-IPO lock-up is set to end roughly 180 days after its Feb. 27, 2026 public trading start, setting up a predictable supply overhang. The stock’s rally into the date implies investors believe AI-native protein design (and the company’s drug-development execution) can absorb the added float risk faster than dilution anxiety can spread.

Revenue base: $31.9MR&D intensity: R&D $224.7M
Read article
Jazz’s Ziihera approval is the HER2 biliary-tract moment—now the investor question is how much profit Merus monetizes and how fast Jazz can move beyond a “niche” BTC label insight cover
Industry News
JAZZ•9 min read

Jazz’s Ziihera approval is the HER2 biliary-tract moment—now the investor question is how much profit Merus monetizes and how fast Jazz can move beyond a “niche” BTC label

The FDA’s Aug. 25, 2026 approval of [Ziihera (zanidatamab-hrii)] for HER2+ first-line gastroesophageal adenocarcinoma (plus the previously approved HER2+ biliary tract cancer label) ends the “yes/no” binary—turning the market focus to launch pace and unit economics. The co-development terms mean a meaningful share of incremental value flows back to Merus’ partner structure via Zymeworks milestone/royalty economics, so the profit split—not just clinical uptake—will decide whether this becomes a durable earnings lever for Jazz Pharmaceuticals rather than a headline-only win.

Ziihera product sales: $15.4MTotal revenues (company-wide): $1.208B
Read article
Revolution Medicines’ RASONQUE cracks pancreatic cancer with a $39,800/30-day price tag—turning KRAS from “undruggable” to monetizable insight cover
Industry News
RVMD•7 min read

Revolution Medicines’ RASONQUE cracks pancreatic cancer with a $39,800/30-day price tag—turning KRAS from “undruggable” to monetizable

Revolution Medicines‘s FDA approval for RASONQUE reframes pancreatic cancer economics around a daily, targeted pill rather than chemotherapy-only leverage. The approval’s core bet is that a KRAS/RAS-driven subset can generate durable, reimbursable demand—starting at a wholesale acquisition cost of $39,800 for a 30-day supply—while established oncology majors face slower switching unless they can match both survival and market access.

FDA approval date: Aug 26, 2026Dose: 300 mg
Read article

2026-08-25

Biotech’s FDA Week Turns Into a “Yes/No” Trade: Jazz (8/25) and Gilead (8/27) each carry near-term repricing risk insight cover
Industry News
10 min read

Biotech’s FDA Week Turns Into a “Yes/No” Trade: Jazz (8/25) and Gilead (8/27) each carry near-term repricing risk

With Jazz’s FDA target action date on Aug 25, 2026 for Ziihera zanidatamab combinations and Gilead’s Aug 27, 2026 target action date for a single-tablet HIV regimen (bictegravir/lenacapavir), this week’s catalysts are fundamentally binary. Investors should treat the market move as an approval-outcome rerate—then quickly map the winners to the downstream uptake bottlenecks (pricing, reimbursement, and label implementation)—rather than anchoring on longer-term product narratives.

Jazz (PDUFA target action date): Aug 25, 2026Gilead (PDUFA action date): Aug 27, 2026
Read article

2026-08-24

Veeva's print will decide whether biotech budgets are cutting “seats”… or just “surprises” in pharma CRM insight cover
Earnings
VEEV•7 min read

Veeva's print will decide whether biotech budgets are cutting “seats”… or just “surprises” in pharma CRM

With Veeva’s Q2 FY2027 report due Aug. 26 (for the quarter ended July 31, 2026), investors get the cleanest read on whether commercial/R&D software demand is resilient even as GLP-1-driven reallocations pressure discretionary spend. The key test is margin quality and AI attach as usage grows—because Veeva has historically protected subscription gross margin even while increasing investment and consumption.

Subscription services gross margin: 86% (Q1 FY2027)Subscription services gross margin: 86% (Q2 FY2026)
Read article

2026-08-23

Ultragenyx's Genglycos wins accelerated approval—but RARE's real proof will be whether manufacturing can keep up insight cover
Industry News
RARE•10 min read

Ultragenyx's Genglycos wins accelerated approval—but RARE's real proof will be whether manufacturing can keep up

The FDA’s accelerated approval for Ultragenyx’s GENGLYCOS (pariglasgene brecaparvovec-opnr) hinges on a surrogate endpoint—reduced daily cornstarch intake—and requires a multi-year confirmatory study. For investors in Ultragenyx, the near-term upside is straightforward; the hardest part is the regulatory- and quality-controlled ramp: the company must sustain manufacturing, lot release, and long-horizon follow-up across eligible patients as AAV8-antibody constraints shape access.

Approval pathway: Accelerated approvalIndication + population: GSDIa, age ≥8
Read article

2026-08-22

Brii’s 42.9% HBsAg-loss readout turns hepatitis B “cure” into a pricing problem, not just a scientific milestone insight cover
Industry News
8 min read

Brii’s 42.9% HBsAg-loss readout turns hepatitis B “cure” into a pricing problem, not just a scientific milestone

Brii 2137.hk reported an end-of-treatment HBsAg-loss rate of 42.9% (42/98) with BRII-179 in a BRII-179 + elebsiran + PEG-IFNα regimen, one of the strongest public functional-cure signals in chronic hepatitis B. If this translates into durable HBsAg loss off treatment, it re-rates the entire industry from “lifelong suppression” to “finite-course, cure-priced” commercial models—benefiting HBV-focused incumbents and RNA- and immune-modality platforms while raising a new diligence question: rebound durability.

Event Date: 2026-08-22Topic Type: Industry News
Read article
FTC’s Caremark deal turns PBM “spread” economics into a compliance liability for CVS, OptumRx, and Cigna insight cover
Industry News
9 min read

FTC’s Caremark deal turns PBM “spread” economics into a compliance liability for CVS, OptumRx, and Cigna

The FTC’s Aug. 21 settlement with Caremark is not just another drug-pricing fight—it forces PBMs to restructure how rebates and reimbursements are handled at the point of sale, including delinking PBM compensation from drug list prices. That directly threatens the margin mechanics that historically let PBMs capture value via spreads and rebate pass-through design, shifting the industry toward fee-style economics.

FTC-stated consumer savings window: Up to $8.5BFTC-stated additional savings unlock: Up to $4.5B
Read article
Gossamer Bio's $250M financing bets seralutinib can still win a reshaped PAH market after Merck's Winrevair label expansion insight cover
Industry News
GOSS · MRK•7 min read

Gossamer Bio's $250M financing bets seralutinib can still win a reshaped PAH market after Merck's Winrevair label expansion

On Aug. 21, Gossamer Bio announced up to $250M of structured private-placement funding to drive seralutinib toward an FDA approval path in pulmonary arterial hypertension. The wager lands right after new Merck Winrevair label evidence strengthened the “clinical worsening” argument—raising the bar for any late-stage PAH competitor that hopes to displace (or add to) standard-of-care.

Total financing (gross): Up to ~$250MCommitted capital: ~$150M
Read article

2026-08-21

argenx wins Phase 3 for autoimmune myositis, pushing its FcRn autoantibody franchise further into chronic immune disease insight cover
Industry News
ARGX•7 min read

argenx wins Phase 3 for autoimmune myositis, pushing its FcRn autoantibody franchise further into chronic immune disease

argenx’s Phase 3 ALKIVIA readout in autoimmune myositis (IMNM + DM) landed a statistically significant primary endpoint, with a 15.4-point Total Improvement Score advantage over placebo. The investor question shifts from “can autoantibodies win?” to “how wide can the FcRn reach go without payer/label friction,” especially as the broader autoantibody-adjacent complex just saw repricing risk after AstraZeneca’s Wainua CARDIO-TTRansform miss.

Primary endpoint (Week 52): MetObserved subtype readouts: IMNM: Met; DM: Not significant
Read article
Roche’s $750M Oregon device fill-finish plan turns reshoring into a combination-product systems build insight cover
Industry News
RHHBY•8 min read

Roche’s $750M Oregon device fill-finish plan turns reshoring into a combination-product systems build

Genentech (Roche’s U.S. subsidiary) will invest about $750M in Hillsboro, Oregon to add a drug-delivery-device fill-finish plant expected to start commercial operations in 2031. That is a contrarian reshoring datapoint versus reports of German companies pulling back U.S. direct investment in H1 2026, and it reframes “onshoring” from just APIs/biologics to full drug-device manufacturing capacity.

Investment size: $750MFacility purpose: Device fill-finish
Read article

What to expect

Evidence-first notes with a visible point of view.

This section collects sharp takes on earnings, shareholder meetings, and market structure. Each new piece should make the thesis, the facts, and the implications obvious within the first few screens.

Expect direct analysis, not generic commentary.

Expect the data to be explicit and the argument to be easy to follow.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

© Plutux Technology Limited 2026